Profile picture

Doctor Peter Kolkhof

BAYER AG, R&D Pharmaceuticals, Wuppertal (Germany)
Follow
Logo ESC

Contributor content

Acute over-additive natriuretic effects by a combination of finerenone and SGLT2 inhibition in rats with an activated renin-angiotensin-aldosterone system: a mechanistic basis for clinical outcomes?
Presentation
Acute over-additive natriuretic effects by a combination of finerenone and SGLT2 inhibition in rats with an activated renin-angiotensin-aldosterone system: a mechanistic basis for clinical outcomes?
Read more
Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage
Presentation
Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage
Read more
The best of two worlds: Vascular protection and decongestion without RAAS stimulation mediated by a novel dual acting V1a/V2 vasopressin receptor antagonist
Presentation
The best of two worlds: Vascular protection and decongestion without RAAS stimulation mediated by a novel dual acting V1a/V2 vasopressin receptor antagonist
Read more
Get the right balance: a novel vasopressin receptor antagonist equally blocks human V1a and V2 receptors and inhibits the release of plasminogen activator inhibitor-1 from cardiomyocytes
Presentation
Get the right balance: a novel vasopressin receptor antagonist equally blocks human V1a and V2 receptors and inhibits the release of plasminogen activator inhibitor-1 from cardiomyocytes
Read more

ESC 365 is supported by

novartis Explore sponsored resources